Colton Groome Financial Advisors LLC bought a new position in shares of Bristol-Myers Squibb (NYSE: BMY – Get Rating) during the 1st quarter, according to its most recent disclosure with the SEC. The fund bought 3,121 shares of the biopharmaceutical company stock, valued at approximately $ 228,000.
A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Mizuho Securities Co. Ltd. lifted its stake in shares of Bristol-Myers Squibb by 239.0% in the 1st quarter. Mizuho Securities Co. Ltd. now owns 339 shares of the biopharmaceutical company stock valued at $ 25,000 after purchasing an additional 239 shares during the period. Steward Financial Group LLC acquired a new position in shares of Bristol-Myers Squibb in the 4th quarter valued at about $ 29,000. Horan Securities Inc. acquired a new position in shares of Bristol-Myers Squibb in the 4th quarter valued at about $ 29,000. Guardian Wealth Management Inc. acquired a new position in shares of Bristol-Myers Squibb in the 4th quarter valued at about $ 32,000. Finally, Leverty Financial Group LLC bought a new stake in Bristol-Myers Squibb in the 4th quarter valued at about $ 37,000. 73.07% of the stock is currently owned by hedge funds and other institutional investors.
A number of analysts recently commented on BMY shares. Raymond James lowered Bristol-Myers Squibb from an “outperform” rating to a “market perform” rating in a research report on Friday, June 3rd. They noted that the move was a valuation call. Citigroup reaffirmed a “buy” rating and issued a $ 90.00 target price on shares of Bristol-Myers Squibb in a research report on Friday, June 3rd. StockNews.com began coverage on Bristol-Myers Squibb in a research report on Thursday, March 31st. They issued a “strong-buy” rating for the company. Barclays boosted their price target on Bristol-Myers Squibb from $ 66.00 to $ 68.00 in a report on Monday, May 2nd. Finally, Guggenheim boosted their price target on Bristol-Myers Squibb from $ 72.00 to $ 80.00 in a report on Monday, May 2nd. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Bristol-Myers Squibb presently has an average rating of “Moderate Buy” and an average target price of $ 74.27.
Bristol-Myers Squibb stock opened at $ 78.88 on Monday. Bristol-Myers Squibb has a 12 month low of $ 53.22 and a 12 month high of $ 79.00. The company has a current ratio of 1.32, a quick ratio of 1.23 and a debt-to-equity ratio of 1.18. The business’s 50 day simple moving average is $ 75.96 and its 200 day simple moving average is $ 70.30. The company has a market cap of $ 167.94 billion, a price-to-earnings ratio of 28.00, a PEG ratio of 1.67 and a beta of 0.49.
Bristol-Myers Squibb (NYSE: BMY – Get Rating) last posted its quarterly earnings data on Friday, April 29th. The biopharmaceutical company reported $ 1.96 EPS for the quarter, beating the consensus estimate of $ 1.92 by $ 0.04. Bristol-Myers Squibb had a return on equity of 48.37% and a net margin of 13.31%. The business had revenue of $ 11.65 billion for the quarter, compared to the consensus estimate of $ 11.34 billion. During the same quarter in the prior year, the business earned $ 1.74 earnings per share. Bristol-Myers Squibb’s revenue for the quarter was up 5.2% on a year-over-year basis. As a group, equities research analysts forecast that Bristol-Myers Squibb will post 7.56 earnings per share for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Monday, August 1st. Investors of record on Friday, July 1st will be paid a $ 0.54 dividend. The ex-dividend date of this dividend is Thursday, June 30th. This represents a $ 2.16 annualized dividend and a yield of 2.74%. Bristol-Myers Squibb’s payout ratio is 76.60%.
In related news, CEO Giovanni Caforio sold 30,000 shares of the stock in a transaction on Monday, June 13th. The stock was sold at an average price of $ 74.04, for a total value of $ 2,221,200.00. Following the sale, the chief executive officer now owns 551,104 shares in the company, valued at $ 40,803,740.16. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Sandra Leung sold 65,000 shares of the stock in a transaction on Monday, June 6th. The stock was sold at an average price of $ 74.89, for a total value of $ 4,867,850.00. Following the completion of the sale, the executive vice president now owns 308,627 shares in the company, valued at approximately $ 23,113,076.03. The disclosure for this sale can be found here. Corporate insiders own 0.09% of the company stock.
Bristol-Myers Squibb Company Profile: (Get Rating)
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke / systemic embolism in NVAF, and for the treatment of DVT / PE; Opdivo for anti-cancer indications; Pomalyst / Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis.
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb (NYSE: BMY – Get Rating).
Receive News & Ratings for Bristol-Myers Squibb Daily: – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Bristol-Myers Squibb and related companies with MarketBeat.com’s FREE daily email newsletter.